NDA 017116 · Specgx LLC
Methadose
Methadone Hydrochloride · Oral
Last checked: Nov 19, 2026Latest source record: Dec 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1973
Mar 14, 1973
Approved uses
1
Original approval plus efficacy supplements
Registered trials
340
70 Phase 3, 35 recruiting
FAERS reports
10,902
9,376 serious, 3,064 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: LIFE-THREATENING RESPIRATORY DEPRESSION, LIFE-THREATENING QT PROLONGATION, ACCIDENTAL INGESTION, ABUSE POTENTIAL, INTERACTIONS WITH DRUGS AFFECTING CYTOCHROME P450 ISOENZYMES and TREATMENT FOR OPIOID ADDICTION Life-Threatening Respiratory Depression Respiratory depression, including fatal cases, have been reported during initiation and conversion of patients to methadone, and even when the drug has been used as recommended and not misused or abused [see Warnings and Precautions ( 5.1 )]. Proper dosing and titration are essential and METHADOSE should only be prescribed by healthcare professionals who are knowledgeable in the use of methadone for detoxification and maintenance treatment of opioid addiction. Monitor for respiratory depression, especially during initiation of METHADOSE or following a dose increase. The peak respiratory depressant effect of methadone occurs later,...
What it is approved for
From the label in effect Apr 27, 2026.
METHADOSE contains methadone, an opioid agonist indicated for the: detoxification treatment of opioid addiction (heroin or other morphine-like drugs). maintenance treatment of opioid addiction (heroin or other morphine-like drugs), in conjunction with appropriate social and medical services. Limitations of Use Methadone products used for the treatment of opioid addiction in detoxification or maintenance programs are subject to the conditions for distribution and use required under 21 CFR, Title 42, Sec 8 [see Dosage and Administration ( 2.1 )] . METHADOSE is an opioid agonist indicated for the: Detoxification treatment of opioid addiction (heroin or other morphine-like drugs). ( 1 ) Maintenance treatment of opioid addiction (heroin or other morphine-like drugs), in conjunction with appropriate social and medical services. ( 1 ) Limitations of Use Methadone products used for the treatment of opioid addiction in detoxification or maintenance programs are subject to the conditions for distribution and use required under 21 CFR, Title 42, Sec. 8. ( 1 , 2.1 )
Mechanism: Methadone hydrochloride is a mu-agonist; a synthetic opioid with multiple actions qualitatively similar to those of morphine, the most prominent of which involves the central nervous system and organs composed of smooth muscle. The methadone withdrawal syndrome, although qualitatively similar to that of morphine, differs in that the onset is slower, the course is more prolonged, and the symptoms are less severe. Some data also indicate that methadone acts as an antagonist at the N-methyl-D-aspartate (NMDA) receptor. The contribution of NMDA receptor antagonism to methadone’s efficacy is...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 14, 1973 Original approval · Type 3 - New Dosage Form Other Important Information from FDA
1 products under this application
- METHADOSE · METHADONE HYDROCHLORIDE 10MG/ML · CONCENTRATE, ORAL · Prescription · TE AA
Clinical trials
Interventional ClinicalTrials.gov studies with "Methadone" as an intervention, any sponsor and status, largest first.
Vanderbilt UniversityAcademic, hospital or other
NCT02625181 · 27,034 participants · Start Jul 2016 · Primary completion Nov 2, 2017
Drug: Propofol; Sevoflurane and 28 more · For: Postoperative Nausea and Vomiting
Sites: Nashville, Tennessee
- MAST Trial: Multi-modal Analgesic Strategies in TraumaPivotal-lookingCompleted
The University of Texas Health Science Center, HoustonAcademic, hospital or other
NCT03472469 · 1,561 participants · Start Apr 2, 2018 · Primary completion Jul 3, 2019
Drug: Acetaminophen IV/PO; Acetaminophen PO and 9 more · For: Nonspecific Pain Post Traumatic Injury
Sites: Houston, Texas
- Combined Therapy of Methadone and DextromethrophanPivotal-lookingStatus unknown
National Cheng-Kung University HospitalAcademic, hospital or other
NCT01189097 · 1,500 participants (planned) · Start Apr 2008 · Primary completion Mar 2011
Drug: Dextromethorphan; Dextromethorphan · For: Opioid Abuse
Sites: Tainan, Taiwan
- Starting Treatment With Agonist Replacement Therapies (START)Pivotal-lookingCompleted
University of California, Los AngelesAcademic, hospital or other
NCT00315341 · 1,269 participants · Start Apr 2006 · Primary completion Aug 2010
Drug: Buprenorphine/naloxone; Methadone · For: Opiate-related Disorders
Sites: Los Angeles, California; Sacramento, California; San Francisco, California · 9 sites in all
- The German Project of Heroin Assisted Treatment of Opiate Dependent PatientsPivotal-lookingCompleted
Universitätsklinikum Hamburg-EppendorfAcademic, hospital or other
NCT00268814 · 1,015 participants · Start Mar 2002 · Primary completion Dec 2003
Drug: Diacetylmorphine; Methadone · For: Opioid Dependence
Sites: Karlsruhe, Germany; Munich, Germany; Hamburg, Germany · 7 sites in all
- Optimizing Outpatient Anesthesia (OSPREy-Outpatient Surgery Pain Relief Enhancement)Pivotal-lookingCompleted
Duke UniversityAcademic, hospital or other
NCT03726268 · 907 participants · Start Nov 29, 2018 · Primary completion Jul 30, 2023
Drug: Methadone; Fentanyl and 3 more · For: Opioid Use; Pain, Postoperative
Sites: Durham, North Carolina
- Office-based Methadone Versus Buprenorphine to Address Retention in Medication for Opioid Use Disorder Treatment.Pivotal-lookingRecruiting
Yale UniversityAcademic, hospital or other
NCT06323824 · 600 participants (planned) · Start Jun 4, 2024 · Primary completion Dec 2028
Drug: Methadone; Buprenorphine (BUP) · For: Opioid Use Disorder
Sites: Oakland, California; San Francisco, California; Denver, Colorado · 6 sites in all
- Efficacy Evaluation of Traditional Chinese Medicine JITAI Combined Comprehensive Model Among Heroin Addicts After DetoxificationPivotal-lookingCompleted
Shanghai Mental Health CenterAcademic, hospital or other
NCT01580163 · 554 participants · Start Sep 2009 · Primary completion Aug 2013
Drug: JITAI Combined with psychological intervention; Methadone and 1 more · For: Heroin Addiction
Sites: Beijing, China; Changsha, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- foetal exposure during pregnancy1,458
- drug withdrawal syndrome neonatal1,434
- toxicity to various agents1,220
- drug dependence1,031
- overdose945
- drug abuse801
- death587
- pain553
- maternal exposure during pregnancy536
- dependence535
- developmental delay507
- learning disability465
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 141 |
| 2005 | 150 |
| 2006 | 133 |
| 2007 | 105 |
| 2008 | 156 |
| 2009 | 285 |
| 2010 | 218 |
| 2011 | 493 |
| 2012 | 1,020 |
| 2013 | 454 |
| 2014 | 156 |
| 2015 | 213 |
| 2016 | 154 |
| 2017 | 276 |
| 2018 | 679 |
| 2019 | 604 |
| 2020 | 720 |
| 2021 | 1,231 |
| 2022 | 864 |
| 2023 | 946 |
| 2024 | 888 |
| 2025 | 618 |
| 2026 | 397 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Methadose (Methadone HCl)
2024 spending
$8K
Beneficiaries
153
439 claims
Per beneficiary
$51
$0.10 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $7,258 |
| 2021 | $4,206 |
| 2022 | $5,561 |
| 2023 | $7,567 |
| 2024 | $7,856 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Buprenorphine versus methadone for the treatment of opioid dependence: a systematic review and meta-analysis of randomised and observational studies.
Degenhardt L, Clark B, Macpherson G, et al. · Lancet Psychiatry 2023 · Meta-Analysis, Systematic Review
- Intraoperative methadone administration and postoperative pain control: a systematic review and meta-analysis.
D'Souza RS, Gurrieri C, Johnson RL, et al. · Pain 2020 · Meta-Analysis, Systematic Review
- Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.
Sordo L, Barrio G, Bravo MJ, et al. · BMJ 2017 · Meta-Analysis, Systematic Review
- Intraoperative Methadone in Next-day Discharge Outpatient Surgery: A Randomized, Double-blinded, Dose-finding Pilot Study.
Kharasch ED, Brunt LM, Blood J, et al. · Anesthesiology 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Methadone--a reevaluation.
Martin WR, Jasinski DR, Haertzen CA, et al. · Arch Gen Psychiatry 1973 · Clinical Trial, Comparative Study
- Effect of Acupuncture for Methadone Reduction : A Randomized Clinical Trial.
Lu L, Chen C, Chen Y, et al. · Ann Intern Med 2024 · Randomized Controlled Trial, Multicenter Study
Sponsor: Specgx LLC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.